PerkinElmer receives approval for mass spectrometry kit
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, recently announced that its NeoBase 2 Non-Derivatized MSMS Kit has received 510(k) clearance from the U.S. Food & Drug Administration (FDA).
Used with a tandem mass spectrometer, this in vitro diagnostic kit is intended for the quantitative measurement and evaluation of traditionallyscreened amino acids and acylcarnitines, as well as succinylacetone, free carnitine, nucleoside and lysophospholipid concentrations.
The NeoBase 2 kit measures up to 51 analytes, including markers for screening of X-linked adrenoleukodystrophy (X-ALD) and adenosine deaminase severe combined immunodeficiency (ADASCID). Currently, it is the only market solution that offers testing for succinylacetone from a dried blood spot punch with a single extraction and incubation step.